Behavioral Intervention Trial for HIV-infected Injection Drug Users

September 26, 2012 updated by: Centers for Disease Control and Prevention

Intervention for Seropositive Injection Drug Users - Research and Evaluation (INSPIRE)

The purpose of this study is to test whether a ten-session behavioral intervention for HIV-infected injection drug users is effective in reducing sex and injection risk behaviors that put others at risk for HIV infection, increasing access to or utilization of HIV primary health care, and increasing adherence to HIV medications.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Behavioral: Peer Mentoring Intervention

Detailed Description

INSPIRE is a four-site (Baltimore, Miami, New York and San Francisco) randomized control trial to develop and evaluate the efficacy of a ten-session intervention for HIV-positive injection drug users. The primary goals of the intervention are to:

decrease sex and injection risk behaviors that put others at risk for HIV infection,
increase access to or utilization of HIV primary health care, and
increase adherence to HIV medications.

The intervention arm consists of 7 group sessions, 2 individual sessions, and one community experience. The control arm consists of 8 group sessions, aiming at controlling for demand (1st session) and attention (8 group sessions). Behavioral assessments and blood draws (for viral load and CD4 testing) occur at baseline, 6, and 12 month follow-up; a 3 month assessment involves behavioral assessment only. 1161 participants took baseline. Of these, 966 were randomized into the study, and 840, 807, and 821 participants took 3, 6, and 12 month follow-up assessments, respectively.

Study Type

Interventional

Enrollment

1000

Phase

Phase 2
Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

United States
- California
  - San Fransisco, California, United States, 94105
    - University of California - San Francisco
- Florida
  - Miami, Florida, United States, 33136
    - University of Miami
- Maryland
  - Baltimore, Maryland, United States, 21231
    - Johns Hopkins University
- New York
  - Bronx, New York, United States, 10467
    - Montefiore Medical Center
  - New York, New York, United States, 10029
    - New York Academy of Medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Genders Eligible for Study

All

Description

Inclusion Criteria:

18 years of age or older
self-identify as a person who has injected drugs in the last 12 months
self-identify as a person who has had sex with at least one opposite sex partner within the last 3 months
self-identify as HIV-seropositive
be confirmed as HIV seropositive through oral fluid (saliva) HIV testing
live in the geographic region under study,
agree to have their blood drawn for CD4 count and viral load testing
be willing to provide basic contact information (for follow-up)
be able to communicate in English
not have participated in the full-pilot of this intervention and not have enrolled previously in the present study.

Exclusion Criteria:

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Interventional Model: Parallel Assignment
Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
- unprotected vaginal/anal sex with HIV-negative or unknown serostatus partners in the past 3 months
- lending needle or sharing cotton, cooker, or rinse water with HIV-negative or unknown serostatus partners in the past 3 months
-health care visits for HIV primary care in the past 6 months
-90% or more adherence to HIV medication yesterday and in the past week

Secondary Outcome Measures

Outcome Measure
-Proportion of HIV status disclosure to sex partners

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centers for Disease Control and Prevention

Collaborators

Health Services Resource Adminstration - HIV/AIDS Bureau

Investigators

Principal Investigator: David W Purcell, JD, PhD, Centers for Disease Control and Prevention

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2001

Primary Completion (Actual)

July 1, 2006

Study Completion (Actual)

July 1, 2006

Study Registration Dates

First Submitted

September 2, 2005

First Submitted That Met QC Criteria

September 2, 2005

First Posted (Estimate)

September 7, 2005

Study Record Updates

Last Update Posted (Estimate)

September 27, 2012

Last Update Submitted That Met QC Criteria

September 26, 2012

Last Verified

September 1, 2012

More Information

Terms related to this study

Keywords

IV drug users

Other Study ID Numbers

CDC-NCHSTP-2864
U22/CCU217990
U22/CCU317999
U22/CCU417998
U22/CCU918003

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.